Anti-pd-l1 antibodies
AssigneeBolt Biotherapeutics, Inc.
InventorsMichael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
Life of this patent
Estimating the term…
Loading patent…
AssigneeBolt Biotherapeutics, Inc.
InventorsMichael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
Estimating the term…
The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.
A programmed death-ligand 1 (PD-L1) binding agent comprising an immunoglobulin heavy chain variable region polypeptide and an immunoglobulin light chain variable region polypeptide, wherein:
A PD-L1 binding agent comprising an immunoglobulin heavy chain variable region of any one of SEQ ID NOs:
A PD-L1 binding agent comprising an immunoglobulin heavy chain variable region polypeptide with an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs:
-24. (canceled)
Dependencies are inferred from the claim text.